Ipamorelin
NOT FDA APPROVEDGrowth-hormone secretagogue
Also known as: growth-hormone secretagogue
Not FDA approved. Sold as a research chemical, labelled not for human consumption.
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 3 registered studies on ClinicalTrials.gov, most advanced Phase 2
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: early human studies confirm it triggers a growth-hormone pulse, relatively selectively. NOT proven: that this produces real body-composition, recovery or anti-aging benefits. Development was discontinued.
What it is
A ghrelin-receptor agonist that prompts the pituitary to release a pulse of growth hormone, in a relatively selective way.
What the research says
Early-phase human studies confirmed it raises GH, but it was never approved and development stopped for its original use.
Common user goals. Not established in controlled trials.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Ipamorelin in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry.
Ipamorelin, the first selective growth hormone secretagogue.
Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.
Metabolism of growth hormone releasing peptides.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Ipamorelin is the intervention being tested.
FDA recalls & enforcement
Ipamorelin has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- No long-term safety data for off-label use.
- Raising GH / IGF-1 has theoretical risks around tissue and abnormal-cell growth.
- Gray-market purity varies.
Doses reported in studies & protocols
Community protocols commonly cite around 200 to 300 mcg per dose. No established clinical dose. This is not a recommendation.
Purity reality
Verify content with a third-party COA before trusting a label.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.